Top

Annals of Surgical Oncology

Published in:

01-07-2007 | Laboratory Research

The Role of Growth Differentiation Factor-9 (GDF-9) and Its Analog, GDF-9b/BMP-15, in Human Breast Cancer

Authors: S. Hanavadi, MS, FRCS, T. A. Martin, PhD, G. Watkins, HND, R. E. Mansel, MS, FRCS, W. G. Jiang, MB BCh, MD

Published in: Annals of Surgical Oncology | Issue 7/2007

Abstract

Background

There has been a recent surge of interest in the role of growth differentiation factors and other bone morphogenic proteins in the development and spread of cancer. In this study we have provided evidence that highlights the significance of growth and differentiation factor-9a (GDF-9a) and GDF-9b (bone morphogenic protein-15, BMP-15) in breast cancer development and progression.

Methods

Primary breast cancer samples (n = 109) and matched background tissues from same patients (n = 33) were processed for frozen section and RNA extraction. Frozen sections from matched tissues were immunostained with GDF-9a and GDF-9b antibodies. Staining intensity was analyzed by computer image analysis. RNA was reverse transcribed and quantified before analysis by quantitative polymerase chain reaction (Q-PCR). Results were expressed as number of transcripts (standardized by β-actin). The data were compared with the clinical outcome of the disease. The biological effects of the molecule were studied using in vitro assays after forced expression in breast cancer cells.

Results

Highly aggressive breast cancer cells did not express GDF-9a. On forced expression of GDF-9a, breast cancer cells became less invasive. These laboratory findings were analyzed against the clinical information. Primary breast cancer samples with good predicted prognosis had a significantly higher level of GDF-9a than in samples with poor predicted prognosis (P = .004). Patients who remained disease-free at the end of a 10-year follow-up had significantly higher levels of both GDF-9a and GDF-9b in their tissue than those with poor clinical outcome (P = .001 and .014, respectively).

Conclusion

Growth differentiation factor-9 family expressed in breast cancer has an inhibitory effect on the progression of human breast cancer.

Pisani P, Parkin DM, Ferlay J. Estimates of worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993; 55:891–903PubMedCrossRef

Urist MR. Bone formation by autoregulation. Science 1965; 150:893–9PubMedCrossRef

Dube JL, Wang P, Elvin J, Lyons KM, Celeste AJ, Matzuk MM. The bone morphogenetic protein 15 gene is X-linked and expressed in oocytes. Mol Endocrinol 1998; 12:1809–17PubMedCrossRef

Phippard DJ, Weber-Hall SJ, Sharpe PT, Naylor MS, Jayatalake H, Maas R, Woo I, Roberts-Clarke D, Francis-West PH, Liu YH, Maxson R, Hill RE, Dale TC. Regulation of MSX-1, MSX-2, BMP-2 and BMP-4during foetal and post-natal mammary gland development. Development 1996; 22:2729–37

Wang EA, Rosen V, D’Alessandro JS, et al. Recombinant human bone morphogenetic protein induces bone formation. Proc Natl Acad Sci U S A 1990; 87:2220–4PubMedCrossRef

Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, Dickson RB. Evidence of transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987; 48:417–28PubMedCrossRef

Clement JH, Sanger J, Hoffken K. Expression of bone morphogenetic protein 6 in normal mammary tissue and breast cancer cell lines and regulation by epidermal growth factors. Int J Cancer 1999; 80(2):250–6PubMedCrossRef

Schwalbe M, Sanger J, Eggers R, Nauman A, Schmidt A, Hoffken K, Clement JH. Differential expression and regulation of bone morphogenetic protein 7 in breast cancer. Int J Oncol 2003; 23(1):89–95PubMed

Arnold SF, Tims E, Mcgrath BE. Identification of bone morphogenetic proteins and their receptors in human breast cancer cells lines: importance of BMP2. Cytokine 1999: 11(12):1031–7PubMedCrossRef

10.

Lacroix M, Siwek B, Marie PJ, Body JJ. Production and regulation of interleukin-11 by breast cancer cells. Cancer Lett. 1998; 127:29–35PubMedCrossRef

11.

Kang Y, Seigel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3(6):537–49PubMedCrossRef

12.

Hanavadi S, Martin TA, Mansel RE, Jiang WG. Interleukin-11 and its receptor expression in human breast cancer. Ann Surg Oncol 2006; 13(6):802–8PubMedCrossRef

13.

Hanavadi S, Martin TA, Mansel RE, Jiang WG. Bone morphogenic protein (BMP)-15 is reduced by Interleukin-11 in human breast cancer cells. Breast Cancer Res Treat 2004; 88(Suppl 1):S248

14.

Incerti B, Dong J, Borsani G, Matzuk MM. Structure of the mouse growth differentiation factor 9 gene. Biochim Biophys Acta 1994; 1222:125–8PubMedCrossRef

15.

McGrath SA, Esquela AF, Lee SJ. Oocyte-specific expression of growth differentiation factor-9. Mol Endocrinol 1995; 9:131–6PubMedCrossRef

16.

Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat 1992; 22(3):207–19PubMedCrossRef

17.

Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. 1. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19:403–10PubMedCrossRef

18.

Chomczynske P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156–159

19.

Jiang WG, Watkins G, Lane J, Douglas-Jones A, Cunnick GH, Mokbel M, Mansel RE. Prognostic value of Rho family and rho-GDIs in breast cancer. Clin Cancer Res 2003; 9(17):6432–40PubMed

20.

Davies G, Jiang WG, Mason MD. Cell–cell adhesion and signaling intermediates in human prostate cancer. J Urol 2000; 163:985–92PubMedCrossRef

21.

Aaltonen J, Laitinen MP, Vuojolainen K, et al. Human growth differentiation factor-9 (GDF-9) and its novel homolog GDF-9b are expressed in oocyte during early folliculogenesis. J Clin Endocrinol Metab 1999; 84:2744–50PubMedCrossRef

22.

Erickson GF, Shimasaki S. The role of oocyte in folliculogenesis. Trends Endocrinol Metab 2000; 11:193–8PubMedCrossRef

23.

Hayashi M, McGee EA, Min G, Klein C, Rose UM, van Duin M, Hsueh AJ. Recombinant growth differentiation factor-9 (GDF-9) enhances growth and differentiation of cultured early ovarian follicles. Endocrinology 1999; 140:1236–44PubMedCrossRef

Title: The Role of Growth Differentiation Factor-9 (GDF-9) and Its Analog, GDF-9b/BMP-15, in Human Breast Cancer
Authors: S. Hanavadi, MS, FRCS
T. A. Martin, PhD
G. Watkins, HND
R. E. Mansel, MS, FRCS
W. G. Jiang, MB BCh, MD
Publication date: 01-07-2007
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 7/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-007-9397-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Role of Growth Differentiation Factor-9 (GDF-9) and Its Analog, GDF-9b/BMP-15, in Human Breast Cancer

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2007

Laparoscopic Prophylactic Oophorectomy Plus N3 Lymphadenectomy for Advanced Rectosigmoid Cancer

Expression Level of Hepatoma-Derived Growth Factor Correlates with Tumor Recurrence of Esophageal Carcinoma

Recurrence and Survival Outcomes after Hepatic Resection with or without Cryotherapy for Liver Metastases from Colorectal Carcinoma

A Meta-Analysis of Quality of Life for Abdominoperineal Excision of Rectum versus Anterior Resection for Rectal Cancer

Risk Criteria and Prognostic Factors for Predicting Recurrences After Resection of Primary Gastrointestinal Stromal Tumor

Yield and Predictors of Radiologic Studies for Identifying Distant Metastases in Melanoma Patients with a Positive Sentinel Lymph Node Biopsy